Research Focus

Nondivisional Cost; Nonexempt Employee on LTD

Recent additions – View all

1. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia

   Journal Article

   Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
   Journal of Clinical Oncology (2006)

   Fulltext@MSK | Save
2. Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia

   Meeting Abstract

   Weiss, M. A.; Lamanna, N.; Kalaycio, M.; Jurcic, J.; Maslak, P.; Gencarelli, A.; Scheinberg, D.; Horgan, D.
   Journal of Clinical Oncology (2004)

   Fulltext@MSK | Save
3. Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms

   Meeting Abstract

   Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J.; Scheinberg, D. A.; Gencarelli, A. N.; Horgan, D.; Weiss, M. A.
   Blood (2004)

   Fulltext@MSK | Save